TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07525141: Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors

Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 66 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,267,720

Rescue Site Savings

+$6,126,120

Unlock Full NCT07525141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07525141 Rescue Dossier →